Nachrichten zur Gilead Sciences Aktie

Gilead Sciences declares $0.75 dividend

…

Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript

GILD earnings call for the period ending September 30, 2023.…

Gilead Sciences, Inc. (GILD) Q3 2023 Earnings Call Transcript

…

Gilead Sciences 3Q results top estimates on cancer and HIV drug sales

Gilead Sciences Inc after Tuesday’s close announced third quarter 2023 adjusted earnings per share (EPS) of $2.29, surpassing the analyst…

Gilead Sciences, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

: Gilead stock rises on top-, bottom-line beats

Gilead Sciences Inc.’s GILD stock climbed 2% in extended trading Tuesday after the pharmaceutical company reported quarterly results that topped…

Gilead Sciences (GILD) Tops Q3 Earnings and Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of 19.90% and 4.08%, respectively, for the quarter ended September 2023. Do the…

How to Invest in Genetics (Updated 2023)

Genetics is the study of genes, their variations and hereditary characteristics, as well as how these traits are passed on…

3 Biotech Stocks With Decent Dividend for a Steady Return

Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year…

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences

NEW YORK and VIENNA, Austria, Oct. 18, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a…

The Zacks Analyst Blog Highlights Walmart, NIKE, TJX, Gilead Sciences and Schlumberger

Walmart, NIKE, TJX, Gilead Sciences and Schlumberger are included in this Analyst Blog.…

: Gilead to pay Assembly Bio an initial $100 million as part of 12-year partnership to develop antiviral drugs

Gilead Sciences Inc. GILD announced Tuesday a 12-year partnership Assembly Biosciences Inc. ASMB to develop antiviral therapies, with an initial…

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

The most recent trading session ended with Gilead Sciences (GILD) standing at $79.20, reflecting a +2% shift from the previouse…

Gilead Sciences: Does The Stocks Reward Outweigh The Risk

…

Gilead Sciences: A Healthy Buy With Solid Dividend

…

Global BREO Ellipta Drugs Research Report 2023-2031 Featuring Major Players - GSK, Akros Pharma, Sun Pharmaceutical Industries, Gilead Sciences, Abbott, & Genosco

Dublin, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The "Global BREO Ellipta Drugs Market Report and Forecast 2023-2031" report…

Sjogrens Syndrome Market Size Increase with Significant CAGR by 2032, Predicts DelveInsight | Key Companies in the Market - Resolve, MorphoSys, Novartis, GlaxoSmithKline, Roche, BMS, TearSolutions, Incyte, Galapagos, Gilead Sciences

Sjogrens syndrome market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies,…

Gilead Sciences goes ex-dividend tomorrow

…

Gilead Sciences: Upgrade

Charlotte (www.aktiencheck.de) - Rating-Update: Die Analysten von BofA Securities stufen die Aktie von Gilead Sciences Inc. (ISIN: US3755581036, WKN 885823,…

Gilead Sciences could jump nearly 30% as biopharma bounces back, says Bank of America

Analyst Geoff Meacham upgraded Gilead to buy from neutral. He increased his target price for the stock by $7 to…

Gilead Sciences prices $2B senior unsecured notes in a public offering

…

Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment

Gileads (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe…

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics

Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog....…